check it out, page-2

G'day Ridge,

I am on this one in a small way too, Riidge.

Personally, I am generally very wary of bios that promise "the next great thing". However, this one is a little different in that whilst they are involved in "the next great thing" (antibody drug development) they are a little bit different than your run o' the mill bio in that their income, at least in the short/medium term, will come from service contracts and technology licencing. (selling shovels in a gold rush).

For me, this is one to take a holding in and then watch and wait to see how well the management performs over the coming months.